Brainstorm Cell Therapeutics Inc.
BCLI
Brainstorm Cell Therapeutics Inc. is a leading biotechnology company committed to the development and commercialization of best-in-class autologous cellular therapies for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis ( ALS , also known as Lou Gehrig's disease), progressive multiple sclerosis ( PMS ), Alzheimer's disease ( AD ), and other n…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$10M
▲ +11.3% YoY
Op. Margin
–
ROIC
-503.97%
▲ +88.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$4M
▲ +23.4% YoY
Op. Cash Flow (TTM)
-$4M
▲ +23.3% YoY
Net Debt
$2M
Cash & Equiv.
$163K
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with BCLI
Brainstorm Cell Therapeutics (BCLI) in two numbers
Questions about Brainstorm Cell Therapeutics
Does Brainstorm Cell Therapeutics (BCLI) pay a dividend?
No. Brainstorm Cell Therapeutics (BCLI) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 11 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in BCLI's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BCLI
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.